title: Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.
abstract: Once hormone resistance has been developed in metastasized prostate cancer, the main aim of therapy is to ensure quality of life. Total androgen blockade which neutralizes the androgens of adrenal origin provides a therapeutic modality which gives +/- 16% objective and +/- 50% subjective response during several months. The two drugs actual available in Belgium are flutamide and cyproterone acetate. Especially flutamide has been used for this purpose. As the number and intensity of side effects is low, this can be considered as a first choice treatment when prostate cancer escapes its first line therapy.
authors.affiliation: University Hospital, Ghent, Belgium.
authors.forename: W
authors.initials: W
authors.lastname: Oosterlinck
authors.forename: P
authors.initials: P
authors.lastname: Mast
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000726:Androgen Antagonists; D017373:Cyproterone Acetate; D005485:Flutamide